Kidney Cancer Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there isuniform NCCN consensus. Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus. Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement). Category 3: The recommendation is based on any level of evidence but reflects major disagreement. All recommendations are category 2A unless otherwise noted. Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Overview In 2008, an estimated 54,390 Americans were diagnosed with kidney cancer and 13,010 died of the disease in the United States.1 Renal cell carcinoma (RCC) comprises approximately 2% of all malignancies, with a median age at diagnosis of 65 years. The rate of RCC has increased 2% per year for the past 65 years. The reason for this increase is unknown. Approximately 90% of renal tumors are RCC, and 85% of these are clear cell tumors.2 Other, less-common cell types include papillary, chromophobe, and Bellini (collecting) duct tumors. Collecting duct carcinoma comprises fewer than 1% of all cases. Medullary renal carcinoma is a variant of collecting duct renal carcinoma and was initially described as occurring in patients who are sickle cell–trait positive. Smoking and obesity are among the risk factors for RCC development. Several hereditary types...
  • 1

    Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008;58:7196.

  • 2

    Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002;11:3742.

    • Search Google Scholar
    • Export Citation
  • 3

    DeVita VT Jr, Hellman S, Rosenberg SA. Cancer Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.

  • 4

    Choyke PL. Hereditary renal cancers. Radiology 2003;226:3346.

  • 5

    Ries LAG, Melbert D, Krapcho M, eds. SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.

    • Search Google Scholar
    • Export Citation
  • 6

    Hricak H, Demas BE, Williams RD. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology 1985;154:709715.

    • Search Google Scholar
    • Export Citation
  • 7

    Janus CL, Mendelson DS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diag Imaging 1991;32:69118.

  • 8

    Dechet CB, Zincke H, Sebo TJ. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol 2003;169:7174.

    • Search Google Scholar
    • Export Citation
  • 9

    Hollingsworth JM, Miller DC, Dunn RL. Surgical management of low-stage renal cell carcinoma: technology does not supersede biology. Urology 2006;67:11751180.

    • Search Google Scholar
    • Export Citation
  • 10

    Shuch B, Lam JS, Belldegrun AS. Open partial nephrectomy for the treatment or renal cell carcinoma. Curr Urol Rep 2006;7:3138.

  • 11

    Leibovich BC, Blute ML, Cheville JC. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;17:10661070.

    • Search Google Scholar
    • Export Citation
  • 12

    Lui KW, Gervais DA, Mueller PR. Radiofrequency ablation: an alternative treatment method of renal cell carcinoma. Chang Gung Med J 2004;27:618623.

    • Search Google Scholar
    • Export Citation
  • 13

    Lewin JS, Nour SG, Connell CF. Phase II clinical trial of interactive MR imaging-guided interstitial radiofrequency thermal ablation of primary kidney tumors: initial experience. Radiology 2004;232:835845.

    • Search Google Scholar
    • Export Citation
  • 14

    Gill IS, Remer EM, Hasan WA. Renal cryoablation: outcome at 3 years. J Urol 2005;173:19031907.

  • 15

    Rouviere O, Bouvier R, Negrier S. Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up. Nat Clin Pract Oncol 2006;3:200213.

    • Search Google Scholar
    • Export Citation
  • 16

    Messing EM, Manola J, Wilding G. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003;21:12141222.

    • Search Google Scholar
    • Export Citation
  • 17

    Clark JI, Atkins MB, Urba WJ. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial. J Clin Oncol 2003;21:31333140.

    • Search Google Scholar
    • Export Citation
  • 18

    Trump DL, Elson P, Propert K. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 1996;15:Abstract 253.

    • Search Google Scholar
    • Export Citation
  • 19

    Kavolius JP, Mastorakos DP, Pavlovich C. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:22612266.

  • 20

    Fossa SD, Kjolseth I, Lund G. Radiotherapy of metastases from renal cancer. Eur Urol 1982;8:340342.

  • 21

    Flanigan RC, Mickisch G, Sylvester R. Cytoreductive nephrectomy in patients with metastatic renal cancer. A combined analysis. J Urol 2004;171:10711076.

    • Search Google Scholar
    • Export Citation
  • 22

    Flanigan RC, Salmon SE, Blumenstein BA. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:16551659.

    • Search Google Scholar
    • Export Citation
  • 23

    Mickisch GH, Garin A, van Poppel H. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966970.

    • Search Google Scholar
    • Export Citation
  • 24

    Negrier S, Escudier B, Lasset C. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:12731278.

    • Search Google Scholar
    • Export Citation
  • 25

    Yang JC, Sherry RM, Steinberg SM. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:31273132.

    • Search Google Scholar
    • Export Citation
  • 26

    Dutcher JP, Fisher RI, Weiss G. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997;3:157162.

    • Search Google Scholar
    • Export Citation
  • 27

    Motzer RJ, Basik J, Murphy BA. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289296.

    • Search Google Scholar
    • Export Citation
  • 28

    Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884896.

  • 29

    Faivre S, Delbaldo C, Vera K. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:2535.

    • Search Google Scholar
    • Export Citation
  • 30

    Motzer RJ, Hutson TE, Tomczak P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115124.

  • 31

    Figlin RA, Hutson TE, Tomczak MD. Overall survival with sunitinib versus interferon (IFN-)alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 5024.

    • Search Google Scholar
    • Export Citation
  • 32

    Wilhelm SM, Carter C, Tang L. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:70997109.

    • Search Google Scholar
    • Export Citation
  • 33

    Moore M, Hirte HW, Siu L. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:16881694.

    • Search Google Scholar
    • Export Citation
  • 34

    Strumberg D, Richly H, Hilger RA. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965972.

    • Search Google Scholar
    • Export Citation
  • 35

    Awada A, Hendlisz A, Gil T. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:18551861.

    • Search Google Scholar
    • Export Citation
  • 36

    Clark JW, Eder JP, Ryan D. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:54725480.

    • Search Google Scholar
    • Export Citation
  • 37

    Szczylik T, Demkow M, Staehler F. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007;25(18S):5025.

    • Search Google Scholar
    • Export Citation
  • 38

    Gibbons JJ, Discafani C, Peterson R. The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract]. Proc Am Assoc Cancer Res 1999;40:Abstract 301.

    • Search Google Scholar
    • Export Citation
  • 39

    Hudes G, Carducci M, Tomczak P. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:22712281.

  • 40

    Yang JC, Haworth L, Sherry RM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427434.

    • Search Google Scholar
    • Export Citation
  • 41

    Escudier B, Pluzanska A, Koralewski P. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:21032111.

    • Search Google Scholar
    • Export Citation
  • 42

    Rini BI, Halabi S, Rosenberg JE. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:54225428.

    • Search Google Scholar
    • Export Citation
  • 43

    Wenzel C, Locker G, Schmidinger M. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney 2002;39:4854.

    • Search Google Scholar
    • Export Citation
  • 44

    Oevermann K, Buer L, Hoffmann R. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 2000;83:583587.

  • 45

    Stadler WM, Halabi S, Ernstoff MS. A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B #90008 [abstract]. J Clin Oncol 2004;22(Suppl 1):Abstract 4515.

    • Search Google Scholar
    • Export Citation
  • 46

    Nanus DM, Garino A, Milowsky MI. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:15451551.

    • Search Google Scholar
    • Export Citation
  • 47

    Motzer RJ, Escudier B, Oudard S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449456.

    • Search Google Scholar
    • Export Citation
  • 48

    Ratain MJ, Eisen T, Stadler WM. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:25052512.

    • Search Google Scholar
    • Export Citation
  • 49

    Escudier B, Eisen T, Stadler WM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125134.

  • 50

    Eisen T, Bukowski RM, Staehler M. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival [abstract]. J Clin Oncol 2006;24(Suppl 1): Abstract 4524.

    • Search Google Scholar
    • Export Citation
  • 51

    Bukowski RM, Eisen T, Szczylik C. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 5023.

    • Search Google Scholar
    • Export Citation
  • 52

    Motzer RJ, Rini BI, Bukowski RM. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:25162524.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 643 516 55
PDF Downloads 461 419 59
EPUB Downloads 0 0 0